Achaogen Культура компании

Dr. Kenneth J. Hillan, M.B., Ch.B., has been the President of R&D at Achaogen, Inc. since January 1, 2018. Dr. Hillan served as the Chief Executive Officer at Achaogen, Inc. from October 3, 2011 to December 31, 2017 and served as its President. Dr. Hillan also manages the Pathology department and its ongoing work in oncology, immunology, vascular biology and other therapeutic areas. He served as Chief Medical Officer of Achaogen, Inc. since March 2011 until July 14, 2014 and served as its President since October 3, 2011. He served as Senior Vice President of Product Development and Head of Clinical Development of Inflammation DBA at Genentech, Inc. He served as a Vice President of Immunology, Tissue Growth and Repair at Genentech, Inc. He served as a Senior Vice President of Clinical Development, Inflammation at Genentech and its Vice President of Research Operations and Pathology; Vice President of Development Sciences; and Vice President of Immunology, Tissue Growth and Repair (ITGR). He served a Vice President of Research Operations and Pathology of Genentech and was responsible for operational management of Genentech's Research organization, ensuring consistent implementation of strategic objectives and improvements in Research productivity. He was into Genentech in 1994 to study the role of hepatocyte growth factor in liver regeneration. He worked at Genentech from August 1994 to April 2011. He also served as Senior Vice President and Head of Clinical Development and Product Development Strategy in Asia-Pacific for Roche in Shanghai, China. He joined the Pathology department as a Scientist in 1996 and served as a Director of Pathology since 1998. He served as a Senior Director of Research Operations of Genentech since 2001. He also is an Honorary Professor of Molecular and Therapeutic Pathology at the University of Leeds. He has been a Director of Zymeworks Inc. since February 3, 2017. He has been a Director of Achaogen, Inc., since October 3, 2011. He served as Director of Relypsa, Inc. since June 19, 2014 to September 2016. He is on the Editorial Advisory Board of the Journal of Pathology and is an ad hoc reviewer for the Journal of Clinical Pathology and the American Journal of Pathology and Liver. He has published more than 40 articles in peer-reviewed journals. He has also authored dozens of scientific publications and is a named inventor on almost 50 issued patents. He holds M.B. Ch.B. (Bachelor of Medicine and Surgery) degree from the Faculty of Medicine at the University of Glasgow University in Scotland in 1983. He was named a Fellow of the Royal College of Surgeons (FRCS) in 1989 and was Named a Member of the Royal College of Pathologists (MRCPath) in 1993.

Mr. Blake Wise has been the Chief Operating Officer of Achaogen, Inc. since October 1, 2015 and also has been its President since February 23, 2017. Mr. Wise is joining Achaogen after 13 years at Genentech, a biotechnology company. He established and led the Cross BioOncology franchise as Vice President, Cross BioOncology. Prior to joining Genentech in 2002, Mr. Wise worked in consumer marketing, e-commerce and online marketing outside of the healthcare industry in leadership positions at Gap and Webvan. During his time at Genentech, Mr. Wise held several other leadership positions of increasing responsibility, including Senior Director, Franchise Head and Life Cycle Leader of the Lytics franchise, with overall commercial responsibility for Genentech's hospital-based Lytics business. He previously served as a Sales Director in BioOncology, Marketing Director in Cystic Fibrosis and Immunology and Interactive Marketing Director where he built Genentech's digital marketing capabilities. Prior to joining Genentech in 2002, Mr. Wise worked in consumer marketing, e-commerce and online marketing outside of the healthcare industry in leadership positions at Gap, Inc. and Webvan. He has been a Director of Calithera Biosciences, Inc. since September 21, 2017. Mr. Wise received his Bachelor of Arts degree in Business Economics from University of California, Santa Barbara and his Masters of Business Administration degree from UC Berkeley's Haas School of Business.

Dr. Nathaniel E. David, also known as Ned, A.B., Ph.D, Co-Founded Unity Biotechnology, Inc. in 2011 and serves as its President. Dr. David serves as a Venture Partner at Arch Venture Partners, L.P. Dr. David served as Chief Executive Officer of Unity Biotechnology, Inc. Dr. David joined Arch Venture Partners in 2009 and focuses on biotechnology, pharmaceuticals and clean tech sectors. Dr. David is building new companies that create disruptive technologies to address global-scale problems by teaming with ARCH. He is the Founder and serves as the Director of Business Development at Takeda California, Inc. He serves as an Entrepreneur-in-Residence (EIR) at Versant Ventures. He serves as a Principal Entrepreneurial Founder at Achaogen, Inc. He is the Co-Founder of Sapphire Energy and Kilimanjaro Energy. He co-founded Kythera Biopharmaceuticals, Inc in 2005; served as an Advisor since October 1, 2015 and served as the Chief Scientific Officer for four years, where he managed all pre-clinical drug discovery efforts. He worked at Cell Genesys, Inc., where he was one of the genetic engineers responsible for developing the Xenomouse. Dr. David co-founded Kythera Biopharmaceuticals, Inc. in 2005 and served as its Chief Science Officer until August 2009. Over the last 15 years, he has co-founded four biotechnology companies that have together raised more than $1.5 billion in financing. He co-founded Syrrx and developed novel methods for the production, purification and crystallization of cell-surface receptors. He also serves as an Executive Director at Cenexys, Inc. Dr. David sits on the Executive Board of the College of Letters and Sciences, University of California, Berkeley and is a Member of the Board of trustees of the UC Foundation and the Buck Institute for Research on Aging. He serves as a Director of Unity Biotechnology, Inc. He served as a Director of Sapphire Energy, Inc and Kilimanjaro Energy. He served as Director of Kythera Biopharmaceuticals, Inc from October 1, 2015. Dr. David holds numerous pending and issued patents in fields such as nanovolume crystallography, antibiotic resistance and aesthetic medicine. In 2002, he was named one of the top 100 innovators in the world under 35 by the M.I.T. Technology Review. Dr. David has experience creating and growing innovative biotechnology companies. Dr. David received a Ph.D. in Molecular and Cellular Biology from the University of California, Berkeley in 1998 and an A.B. in Biology and Biochemistry from Harvard College in 1990.

Mr. Tobin C. Schilke, also known as Toby, has been the Chief Financial Officer at Achaogen, Inc. since July 5, 2016. Mr. Schilke joined Achaogen??? after 13 years at ??? Roche/Genentech. He served as the Chief Financial Officer and Company Director of Roche Products Limited in the United Kingdom. In this role,??? Mr. Schilke was responsible for financial planning and analysis (FP&A), accounting, legal & financial compliance, supply chain, procurement and site services for Roche's Pharma presence in the UK. Previously, Mr. Schilke had overall FP&A responsibility for ??? Genentech's ??? Commercial BioOncology business and prior to Genentech, led a number of successful acquisition and spin-out deals as a member of the Roche Corporate M&A team. Mr. Schilke received a Bachelor of Science degree in Chemical Engineering from Lafayette College in Easton, Pennsylvania, a Masters of Science degree from University of California in Berkeley, California and a Masters of Business Administration degree from Cornell University's Johnson Graduate School of Management, New York.

Dr. Floyd E. Romesberg, Ph.D. is renowned scientist and professor of chemistry at The Scripps Research Institute. Dr. Romesberg is the Scientific Founder of Synthorx Inc. He was scientific co-founder of RQx Pharmaceuticals. He served as Principal Scientific Founder and Advisor of Achaogen, Inc. Dr. Romesberg is an expert on DNA replication, repair and mutation. His work examining the role of gene products in the active introduction of mutations is the basis of the Achaogen technology platform. He was Assistant Professor of Chemistry at The Scripps Research Institute. Dr. Romesberg has managed a research group at The Scripps Research Institute since 1998. He serves as a Director of RQx Pharmaceuticals, Inc. and Synthorx Inc. He has been a Member of Scientific Advisory Board at Molecular Assemblies, Inc. since March 2017. He served as a Member of Scientific Advisory Board at Helicos BioSciences Corporation. Dr. Romesberg is best known for developing unnatural base pairs for the expansion of the genetic alphabet and is also working to develop novel antibiotics, as well as to understand how evolution tailors protein dynamics and how cellular stress and DNA damage induce cell-cycle checkpoint responses and mutations. He is the recipient of multiple academic awards, including the NSF Career Award in 2004, the Susan B. Komen Breast Cancer Foundation Award in 2003, the Dreyfus Teacher-Scholar Award in 2003, the Baxter Foundation Fellow Award in 2002 and the Mac Nevin Award in 1987. Dr. Romesberg received his Ph.D./doctorate in physical organic Chemistry from Cornell University and Bachelor of Science degree in chemistry from The Ohio State University.

Zeryn Sarpangal serves as the CFO for Achaogen. Zeryn started at Achaogen in October of 2018. Zeryn is based in the San Francisco Bay Area.

Tobin Schilke serves as the CFO for Achaogen. Tobin started at Achaogen in December of 2016. Tobin is based in the San Francisco Bay Area.

Marcel Roche serves as the VP Finance & Accounting for Achaogen. Marcel started at Achaogen in March of 2018. Marcel is based in the San Francisco Bay Area.

Jeannie Lloyds serves as the VP, Hospital Sales for Achaogen. Jeannie started at Achaogen in May of 2017. Jeannie is based in the San Francisco Bay Area.